Understanding how a drug changes the body matters for who can benefit from it. If heart protection comes from shifting inflammation or improving vessel function, the medicine might help people who struggle to lose weight or who already have a healthy body mass index. Clinicians will want to weigh that evidence alongside safety, access, and long-term outcomes as they consider expanding treatment options.
This research ties directly into how we support human potential: healthier hearts mean more years of active, productive life and greater inclusion for people facing chronic disease. Follow the full article to explore the mechanisms researchers are testing and what this could mean for widening access to therapies that protect cardiovascular health.
Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems tied not just to slimming down but to deeper biological effects on inflammation, blood pressure, and vessel health. Researchers say this could expand who qualifies for the drug.